The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues

DSpace/Manakin Repository

The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Kaufman, Robert en_US
dc.date.accessioned 2012-07-06T20:09:54Z
dc.date.issued 2004 en_US
dc.identifier.citation The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues (2004 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8963868
dc.description.abstract The regulation off-label drugs is a complicated and controversial area of the law. Regulators must protect patients’ safety without interfering with physicians’ practice of medicine or manufacturers’ First Amendment rights. The recent Neurontin decisions, which apply the doctrine of false claims to prescription drug regulation, only adds additional complexity. This paper explores the federal government’s attempts to regulate the promotion of off-label drugs. It discussed the advantages and disadvantages of off-label marketing, the current regulatory environment, and the implications of the Neurontin lawsuit. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject neurontin en
dc.title The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-07-06T20:09:54Z

Files in this item

Files Size Format View
Kaufman.pdf 232.8Kb PDF View/Open
Kaufman.rtf 239.9Kb RTF file View/Open
Kaufman.html 245.0Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters